AzTrials
AzTrials

Foot Ulcer ChronicNCT02307448

Effectiveness of Autologous Platelet Rich Plasma in the Treatment of Chronic Non-Healing Wounds

A study testing Platelet Rich Plasma in people with Foot Ulcer Chronic and Skin Ulcer Venous Stasis Chronic, run by ACR Biologics, LLC at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This investigation plans to initiate the healing of chronic wounds by providing a concentrated platelet and growth factor therapy directly to the wound site by topical delivery. This therapy will be derived from autologous platelet rich plasma (PRP), an emerging surgical and wound care treatment. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
What is being tested?
Platelet Rich Plasma
Type of treatment
Surgery or procedure
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
80 participants
Where
1 siteUnited States
Study dates
Aug 2015to Dec 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

6.2 Inclusion Criteria

  • Male or female ≥ 18 years of age.
  • Wound must be diagnosed as Diabetic Foot Ulcers (DFU), Venous Ulcers (VU), or Pressure Ulcers (PU) with duration greater than 30 days at first visit/patient screening.
  • If more than one non-healing wound is present, the largest wound will be selected and must be at least 2cm in size.
  • Wound must be classified as Wagner 1 - 3 on the Wagner classification system. Wagner's Classification System Grade 1 Superficial ulcer without subcutaneous tissue involvement Grade 2 Penetration through the subcutaneous tissue (bone, tendon, ligament or joint capsule) Grade 3 Osteitis, abscess or osteomyelitis Grade 4 Gangrene of the forefoot Grade 5 Gangrene of the entire foot
  • There must be at least 2 cm between the index wound and other wounds; if all wounds are closer than 2 cm, the patient should not be enrolled (screen failure).
  • Wound must be clinically non-infected (A swab or deep tissue culture shall be performed at the discretion of the provider).
  • If a female of childbearing potential, the patient must have a negative serum pregnancy test at screening.
  • Patient has the capacity to understand and consent to be in the study. Written informed consent must be obtained from either the patient or the patient's legally acceptable representative prior to screening activities.
  • Platelet count ≥ 75,000 (according to CBC)
  • Hemoglobin (Hgb) level > 9 g/dL (according to CBC)
  • Hematocrit (HCT or Ht) level > 27% (according to CBC)
  • Ankle-Brachial Index (ABI) Test > 0.7

6.3 Exclusion Criteria

  • Male or female <18 years of age
  • Patients with known sensitivity to components of the PRP kit (calcium chloride, thrombin, collagen, acid citrate dextrose solution A (ACDA).
  • Wound is not a Diabetic Foot Ulcers (DFU), Venous Ulcer (VU), or Pressure Ulcer (PU) at duration of greater than 30 days at first visit/patient screening.
  • Wounds smaller than 2cm will be excluded. Exclusion criteria do not include maximum wound size or age.
  • Wound that is classified as Wagner 4 - 5 on the Wagner classification system. Wagner's Classification System Grade 1 Superficial ulcer without subcutaneous tissue involvement Grade 2 Penetration through the subcutaneous tissue (bone, tendon, ligament or joint capsule) Grade 3 Osteitis, abscess or osteomyelitis Grade 4 Gangrene of the forefoot Grade 5 Gangrene of the entire foot
  • There is less than 2 cm between the index wound and other wounds; if all wounds are closer than 2 cm, the patient should not be enrolled (screen failure).
  • Wound is clinically infected. (A swab or deep tissue culture shall be performed at the discretion of the provider).
  • Presence of non-treated osteomyelitis.
  • If female, patient is pregnant, nursing or plans to become pregnant during the duration of the trial.
  • Patients who are cognitively impaired and do not have a healthcare proxy.
  • Platelet count < 75,000 (according to CBC)
  • Hemoglobin (Hgb) level ≤ 9 g/dL (according to CBC)
  • Hematocrit (HCT or Ht) level ≤ 27% (according to CBC)
  • Ankle-Brachial Index (ABI) Test ≤ 0.7
  • Patient has lymphedema.
  • Received electrostimulation, hyperbaric treatments, systemic corticosteroids, growth factors or any cell or tissue derived products for any wounds 30 days prior to entry into the study. (Except for patients receiving inhaled corticosteroid treatments for COPD)
  • Received radiation therapy or chemotherapy within previous 3 months.
  • Patient has inadequate venous access for repeated blood draw required for PRP preparation.
  • Concurrent participation in a clinical trial in which an investigational agent is used.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • TriHealth Hatton Research Institute | Bethesda North Hospital

    Cincinnati, Ohio, 45242

Other trials in United States

About this study

This investigation plans to initiate the healing of chronic wounds by providing a concentrated platelet and growth factor therapy directly to the wound site by topical delivery. This therapy will be derived from autologous platelet rich plasma (PRP), an emerging surgical and wound care treatment. This investigation aims to demonstrate that patients with chronic, non-healing wounds treated with autologous PRP and standard medical care have a reduction in wound volume and improved healing rate that results in patient-centered clinically significant health outcomes as compared to patients treated with standard medical care only.

Read the detailed description

This is a multicenter randomized controlled trial, with a single-blind parallel design. 1,500 subjects are planned to enroll in the study. Each subject will be assigned to the treatments in random order. The stratified permuted block randomization method will be applied to the patient assignment. In addition to three study populations, i.e., DFU, VU and PU, and study centers, stratification will be based on one overall variable, (1) nutritional status (Low: Prealbumin <12mg/d vs. moderate: Prealbumin >= 12 mg/d) and one variable for each wound type. Diabetic food ulcer will be based on offloading (2a) (Specialty shoes vs. Total contact cast), pressure ulcer will be based on offloading (2b) (mattress vs. cushion), and venous leg ulcer will be based on compression (2c)(Low: <10 mmHG vs. High: >=30mmHG). Randomization will proceed within strata according to a permuted block scheme with a block size, or balancing interval, varying randomly between 2, 4 or 6. The primary endpoint will be evaluated by a blinded physician to avoid the bias.

Total duration of each patient in the study is expected to be 20 weeks.

Being tested
Platelet Rich Plasma, Standard of Care
Medical subject headings
Pressure Ulcer

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Platelet Rich PlasmaProcedure or surgery

    Also called PRP

    Patients will receive weekly PRP treatments with standard of care.

  • Standard of CareProcedure or surgery

    Patients will receive weekly standard of care.

Study groups in NCT02307448
Study groupRoleWhat they receive
PRP GroupActive comparatorPatients will receive weekly PRP treatments
Receives: Procedure: Platelet Rich Plasma
Standard of CarePlacebo comparatorPatients will receive weekly standard of care.
Receives: Procedure: Standard of Care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Wound Closure

    The primary objective of this trial is to evaluate increasing the proportion of wounds with complete closure within 20 weeks of initial treatment

    Measured: 20 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Dec 2014 (estimated)
  2. Study startAug 2015
  3. Primary completionDec 2022
  4. Study completionDec 2022

Why it stopped: Lack of patient enrollment and lack of reimbursement

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
80 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02307448
Sponsor's protocol ID
10312014
Status last verified
Jan 2023
First submitted
2 Dec 2014
Last updated
1 Feb 2023
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Platelet Rich Plasma in people with Foot Ulcer Chronic and Skin Ulcer Venous Stasis Chronic, run by ACR Biologics, LLC at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 1 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Lack of patient enrollment and lack of reimbursement). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Wound Closure (time frame: 20 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Feb 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in